Department of Biochemistry, ELTE Eötvös Loránd University, Budapest 1117, Hungary.
Department of Biochemistry, ELTE Eötvös Loránd University, Budapest 1117, Hungary; Institute of Genetics and of Molecular and Cellular Biology, IGBMC, Strasbourg 67400, France.
Structure. 2020 Aug 4;28(8):943-953.e4. doi: 10.1016/j.str.2020.05.001. Epub 2020 May 21.
To fully understand the environmental factors that influence crystallization is an enormous task, therefore crystallographers are still forced to work "blindly" trying as many crystallizing conditions and mutations to improve crystal packing as possible. Numerous times these random attempts simply fail even when using state-of-the-art techniques. As an alternative, crystallization chaperones, having good crystal-forming properties, can be invoked. Today, the almost exclusively used such protein is the maltose-binding protein (MBP) and crystallographers need other widely applicable options. Here, we introduce annexin A2 (ANXA2), which has just as good, if not better, crystal-forming ability than the wild-type MBP. Using ANXA2 as heterologous fusion partner, we were able to solve the atomic resolution structure of a challenging crystallization target, the transactivation domain (TAD) of p53 in complex with the metastasis-associated protein S100A4. p53 TAD forms an asymmetric fuzzy complex with the symmetric S1004 and could interfere with its function.
要全面了解影响结晶的环境因素是一项艰巨的任务,因此结晶学家仍然被迫“盲目”工作,尽可能多地尝试各种结晶条件和突变以改善晶体堆积。即使使用最先进的技术,这些随机尝试也经常失败。作为替代方法,可以调用具有良好成晶特性的结晶伴侣。如今,几乎专门使用的这种蛋白质是麦芽糖结合蛋白(MBP),结晶学家需要其他广泛适用的选择。在这里,我们介绍 annexin A2(ANXA2),它的成晶能力与野生型 MBP 一样好,如果不是更好的话。使用 ANXA2 作为异源融合伴侣,我们能够解决一个具有挑战性的结晶靶标,即 p53 的转录激活结构域(TAD)与转移相关蛋白 S100A4 的原子分辨率结构。p53 TAD 与对称的 S1004 形成不对称的模糊复合物,并可能干扰其功能。